A Boy with Chronic Active EBV Infection Presented as Mosquito Bite Hypersensitivity Progressed to Fatal Hemophagocytic Lymphohistiocytosis due to NK Cell Neoplasm

Chronic active Epstein-Barr virus (CAEBV) infection is characterized by recurrent infectious mononucleosis (IM)-like symptoms and an unusual pattern of anti-EBV antibodies. We report a boy with CAEBV who progressed to aggressive hemophagocytic lymphohistiocytosis (HLH) with NK cell neoplasm. A 19-ye...

Full description

Saved in:
Bibliographic Details
Published inClinical pediatric hematology-oncology Vol. 26; no. 2; pp. 95 - 98
Main Authors Lee, Jin Ah, Han, Seung Beom, Chung, Nack Gyun, Kang, Jin Han, Kim, Myungshin, Jeong, Dae Chul
Format Journal Article
LanguageEnglish
Published The Korean Society of Pediatric Hematology-Oncology 01.10.2019
대한소아혈액종양학회
Subjects
Online AccessGet full text
ISSN2233-5250
2233-5250
DOI10.15264/cpho.2019.26.2.95

Cover

More Information
Summary:Chronic active Epstein-Barr virus (CAEBV) infection is characterized by recurrent infectious mononucleosis (IM)-like symptoms and an unusual pattern of anti-EBV antibodies. We report a boy with CAEBV who progressed to aggressive hemophagocytic lymphohistiocytosis (HLH) with NK cell neoplasm. A 19-year-old adolescent boy was admitted with fever and a history of recurrent IM-like symptoms following mosquito bites since the age of 6 years. His condition was diagnosed as CAEBV with atypical lymphocytosis and an unusual pattern of anti-EBV antibodies. His symptoms subsided during treatment with steroids and cyclosporine, although the EBV genome load kept increasing for several years. He was re-admitted after follow-up loss for 8 years, and his clinical and laboratory findings confirmed HLH and high titer of the EBV genome. Bone marrow analysis with flow cytometry showed hemophagocytosis with compatible NK cell neoplasm. He rapidly progressed to pulmonary infection and expired soon after. We conclude that hematopoietic stem cell transplantation may be a potential therapeutic modality for treating CAEBV before serious EBV manifestations.
ISSN:2233-5250
2233-5250
DOI:10.15264/cpho.2019.26.2.95